Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M418Revenue $M38.3Net Margin (%)-281.7Altman Z-Score-6.7
Enterprise Value $M327EPS $-0.5Operating Margin %-269.3Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.3Pre-tax Margin (%)-281.7Higher ROA y-yN
Price/Book7.810-y EBITDA Growth Rate %-28.1Quick Ratio3.3Cash flow > EarningsY
Price/Sales10.85-y EBITDA Growth Rate %-24.0Current Ratio3.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-35.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-128.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M243ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARNAKen Fisher 2016-03-31 Sold Out $1.41 - $1.97
($1.61)
$ 1.727%Sold Out0
ARNAKen Fisher 2015-12-31 Add$1.7 - $2.4
($2.04)
$ 1.72-16%Add 0.91%11,100
ARNAKen Fisher 2013-12-31 Buy $4.08 - $6.66
($5.22)
$ 1.72-67%New holding11,000
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
($1.7)
$ 1.721%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
($1.58)
$ 1.729%New holding13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WOODS RANDALL EDirector 2015-03-30Sell76,268$4.49-61.69view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-03-17Sell70,000$5-65.6view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell45,000$6.26-72.52view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell50,000$5.49-68.67view
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-70.6view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-70.6view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-75.6view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-75.43view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-72.74view
Nova Tina SusanDirector 2014-04-14Sell35,000$6.22-72.35view

Quarterly/Annual Reports about ARNA:

News about ARNA:

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Arena Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
Arena Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
New Strong Sell Stocks for April 21st Apr 21 2016
Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study Apr 13 2016
New Strong Sell Stocks for April 13th Apr 13 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 12 2016
Arena Pharma (ARNA) Stock Advancing on Favorable Trial Results Apr 12 2016
Arena Pharmaceuticals Reports Favorable Results from Phase 1b Multiple-Ascending Dose Clinical Trial... Apr 12 2016
Arena Pharmaceuticals Reports Favorable Results from Phase 1b Multiple-Ascending Dose Clinical Trial... Apr 12 2016
Trending Now: ARNA Apr 06 2016
Arena Pharmaceuticals Extends Its Winning Streak (ARNA, CELG) Mar 28 2016
Analyst Report; Expected FDA Decisions Around the Corner Mar 28 2016
Stocks to Watch for Tuesday 3/22/2016, If You Choose Mar 22 2016
Why Arena Pharmaceuticals Surged 10% Last Week (ARNA) Mar 21 2016
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March... Mar 21 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Mar 21 2016
Hedge Funds Think These 4 Marijuana Stocks Are Pretty Dope Mar 16 2016
How Speculation Drives Investment in Arena Pharmaceuticals (ARNA) Mar 14 2016
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Amgen, Regeneron Pharmaceuticals and... Mar 14 2016
Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid Mar 11 2016
ARENA PHARMACEUTICALS INC Financials Mar 08 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)